| Rx0000194 |
Cameron Pharmaceuticals, LLC |
06/30/2020 |
42494040901 |
Chlordiazepoxide Clidinium Bromide 5mg/2.5mg 100 Capsules |
06/11/2020 |
1246.00 |
1395.00 |
None |
Non-innovator Multiple Source Drug |
60226 |
None |
Approved Authorized Generic. |
None |
See below for the Medispan Listing for 42494-0409-01:
Price Rx
Product Information
User: Michael Venters June 22, 2020
Medi-Span Classification
Drug Group
Drug Class
Drug Subclass
Drug Name
49
49-10
49-10-99
49-10-99-02-45
ULCER DRUGS/ANTISPASMODICS/ANTICHOLINERGICS
Antispasmodics
Anticholinergic Combinations
Chlordiazepoxide HCl-Clidinium Bromide
Drug Range 46-52 Gastrointestinal Agents
GPI Name 49-10-99-02-45-01-10 Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG
GPPC 02685-003 Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG, 100 Each, Bottle
Other Classifications
AHFS 12080800 Antimuscarinics/Antispasmodics
USC 23130 GI ANTISPASMODIC, W/TRANQUILIZERS
Drug Base Name 49-10-99-02 Anticholinergic Combination - Two Ingredient
Drug Name And Dosage Form 49-10-99-02-45-01 Chlordiazepoxide HCl-Clidinium Bromide Capsule
42494-0409-01
NDC/UPC/HRI Product Name Package Size Package SUM
chlordiazePOXIDE-Clidinium Oral Capsule 5-2.5 MG 100 EA
Package Qty Package Description Labeler Name Labeler Code
1 Bottle CAMERON PHARMACEUTICALS 42494
Page 1 of 5 © Copyright 2020 Clinical Drug Information, LLC |
None |
09/25/2017 |
Bausch Health |
0 |
None |
No upfront payment to be acquire authorized generic |
1395.00 |
0.00 |
2016 |
1395.00 |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=439 |
None |
| Rx0000139 |
Chiesi USA |
06/30/2020 |
52609000601 |
Ferriprox film-coated tablets 500mg 100ct |
04/03/2020 |
509.05 |
6872.12 |
06/28/2021 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2011 |
3168.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000139 |
Chiesi USA |
06/30/2020 |
52609450207 |
Ferriprox Solution for oral use 100mg/ml 500ml bottle |
04/03/2020 |
509.05 |
6872.12 |
10/20/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
01/06/2020 |
ApoPharma Inc. |
None |
1 |
No comment. |
6363.07 |
5843.04 |
2015 |
4533.00 |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chieisi USA believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. |
| Rx0000146 |
Circassia Pharmaceuticals |
03/31/2020 |
72124000202 |
Tudorza Pressair Inhalation Powder 400mcg 30 actuations |
01/01/2020 |
25.74 |
285.74 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
175.88 |
170.75 |
2015 |
140.70 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective July 1st; however, Tudorza, under the new NDC, was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01. |
| Rx0000146 |
Circassia Pharmaceuticals |
03/31/2020 |
72124000201 |
Tudorza Pressair Inhalation Powder 400mcg 60 actuations |
01/01/2020 |
51.48 |
571.48 |
03/13/2029 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
07/01/2019 |
AstraZeneca |
218840450 |
None |
The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. |
351.75 |
341.51 |
2015 |
281.40 |
None |
Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective July 1st; however, Tudorza, under the new NDC, was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020191 |
Rubraca 200mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=420, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=423 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020291 |
Rubraca 250mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=421, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=424 |
Product licensing was not acquired within the last 5 years. |
| Rx0000030 |
Clovis Oncology, Inc |
03/31/2020 |
69660020391 |
Rubraca 300mg, 60 tabs/bottle |
01/19/2020 |
390.00 |
8351.00 |
08/17/2035 |
Single Source Drug |
None |
1 |
Manufacturing costs, inflation costs, and market dynamics allow the increase to remain within market value |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=422, https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=425 |
Product licensing was not acquired within the last 5 years. |
| Rx0000320 |
CMP Pharma |
12/31/2020 |
46287002004 |
CaroSpir spironolactone oral suspension 25mg/5ml 18ml |
10/01/2020 |
28.90 |
349.70 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000320 |
CMP Pharma |
12/31/2020 |
46287002001 |
CaroSpir spironolactone oral suspension 25mg/5ml 473ml |
10/01/2020 |
98.20 |
1253.00 |
10/28/2036 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865024502 |
NUCYNTA ER-100MG-100 TABLET |
01/01/2020 |
75.26 |
835.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011660 |
NUCYNTA ER-100MG-100 TABLETS |
01/01/2020 |
75.26 |
835.46 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865025002 |
NUCYNTA ER-150MG-100 TABLET |
01/01/2020 |
97.10 |
1077.89 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510017460 |
NUCYNTA ER-150MG-100 TABLETS |
01/01/2020 |
97.10 |
1077.89 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865026002 |
NUCYNTA ER-200MG-100 TABLET |
01/01/2020 |
123.26 |
1368.32 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510023260 |
NUCYNTA ER-200MG-100 TABLETS |
01/01/2020 |
123.26 |
1368.32 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865026501 |
NUCYNTA ER-250MG-100 TABLET |
01/01/2020 |
154.21 |
1711.91 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510029160 |
NUCYNTA ER-250MG-100 TABLETS |
01/01/2020 |
154.21 |
1711.91 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865024002 |
NUCYNTA ER-50MG-100 TABLET |
01/01/2020 |
40.69 |
451.74 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510005860 |
NUCYNTA ER-50MG-100 TABLETS |
01/01/2020 |
40.69 |
451.74 |
09/22/2028 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865023002 |
NUCYNTA IR-100MG-100 TABLET |
01/01/2020 |
98.07 |
1088.71 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510010010 |
NUCYNTA IR-100MG-100 TABLETS |
01/01/2020 |
98.07 |
1088.71 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865021002 |
NUCYNTA IR-50MG-100 TABLET |
01/01/2020 |
62.98 |
699.13 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510005010 |
NUCYNTA IR-50MG-100 TABLETS |
01/01/2020 |
62.98 |
699.13 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
69865022002 |
NUCYNTA IR-75MG-100 TABLET |
01/01/2020 |
73.58 |
816.86 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510007510 |
NUCYNTA IR-75MG-100 TABLETS |
01/01/2020 |
73.58 |
816.86 |
06/27/2025 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011510 |
XTAMPZA ER-13.5MG-100 CAPSULES |
01/01/2020 |
64.94 |
720.92 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510012010 |
XTAMPZA ER-18MG-100 CAPSULES |
01/01/2020 |
82.36 |
914.25 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510013010 |
XTAMPZA ER-27MG-100 CAPSULES |
01/01/2020 |
114.57 |
1271.80 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510014010 |
XTAMPZA ER-36MG-100 CAPSULES |
01/01/2020 |
141.01 |
1565.39 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000200 |
Collegium Pharmaceuticals |
03/31/2020 |
24510011010 |
XTAMPZA ER-9MG-100 CAPSULES |
01/01/2020 |
44.12 |
489.82 |
09/02/2036 |
Single Source Drug |
None |
1 |
We have never been profitable and have incurred net losses in each year since inception. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations. These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2020 |
66220028708 |
Caldolor (ibuprofen) injection 800 mg/8ml for intravenous use; sold by the tray (25 vials/ tray) |
01/02/2020 |
32.13 |
433.78 |
09/14/2030 |
Innovator Multiple Source Drug |
373635 |
None |
Our cost of goods and manufacturing is based on forecasted demand.If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increases, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years. |
| Rx0000230 |
Cumberland Pharmaceuticals |
03/31/2020 |
66220016010 |
Vaprisol (conivaptan hydrochloride) for intravenous use: 20 mg, injection, one 5% dextrose 100 mL Plastic Container sold in multiples of 10 cartons/case |
01/02/2020 |
52.41 |
707.56 |
None |
Single Source Drug |
1804 |
None |
Our cost of goods and manufacturing is based on forecasted demand.If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increases, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000230 |
Cumberland Pharmaceuticals |
12/31/2020 |
66220016010 |
Vaprisol (conivaptan hydrochloride) for intravenous use: sold in multiples of 10 cartons/case |
10/01/2020 |
61.13 |
825.30 |
12/15/2019 |
Single Source Drug |
710 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
Not applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired within the last five years |
| Rx0000230 |
Cumberland Pharmaceuticals |
12/31/2020 |
62847000101 |
Vibativ (telavancin) for injection, for intravenous use: sold in multiples of 10 individually packaged 750 mg single-dose vials/carton. |
10/01/2020 |
11.98 |
491.16 |
01/01/2027 |
Single Source Drug |
33707 |
None |
Our cost of goods and manufacturing is based on forecasted demand. If our PO's are less than we submit to our contract manufacturer, they raise their prices to us. Also, as the cost of manufacturing and raw materials increase, the price of product will subsequently increase. |
None |
not applicable |
None |
11/12/2018 |
Theravance Biopharma, Inc |
25000000 |
None |
None |
431.91 |
412.28 |
2009 |
374.94 |
None |
None |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
64597031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Box (sumatriptan succinate exhale powder) 11mg |
01/01/2020 |
78.40 |
870.40 |
10/24/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847031108 |
Onzetra Xsail Nasal Exhaler Powder 4 Dose Kit (sumatriptan succinate exhale powder) 11mg |
02/03/2020 |
78.40 |
870.40 |
10/20/2034 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
09/25/2019 |
Avanir Pharmaceuticals |
4480000 |
None |
None |
792.00 |
792.00 |
2016 |
488.00 |
None |
For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC, as manufacturer, are filling orders only for the Currax NDC-42847031108, the former (Avanir) NDC-64597031108 is still in the market place and may be ordered by pharmacies from their wholesalers. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847010330 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 3mg |
01/01/2020 |
44.92 |
498.90 |
09/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
03/31/2020 |
42847010630 |
Silenor Oral Tablet 30ct (doxepin hydrochloride) 6mg |
01/01/2020 |
44.92 |
498.90 |
09/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
453.98 |
428.28 |
2010 |
165.14 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported. |
| Rx0000181 |
Currax Pharmaceuticals LLC |
06/30/2020 |
42847085009 |
Treximet 9 tab/pk sumatriptan/naproxen 85 mg/500 mg |
06/26/2020 |
105.21 |
1168.11 |
04/02/2026 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Pharmaceuticals |
None |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
967.23 |
880.09 |
2015 |
625.00 |
None |
Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Pharmaceuticals. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC maintains no liability for pricing and pricing history prior to April 30, 2019.
Since the acquisition was in bankruptcy, the asset purchase amount is not reported nor public. |